September 25, 2014 / 6:20 AM / 3 years ago

BRIEF-Nicox unveils positive Phase III results for eye drug

1 Min Read

Sept 25 (Reuters) - Nicox :

* Nicox and Valeant Pharmaceuticals announce positive top-line results from pivotal phase 3 studies conducted with Vesneo (latanoprostene bunod)

* Says studies met their primary endpoint and showed positive results on a number of secondary endpoints

* Says product has peak sales potential of around $500 million+ in U.S. and over $1 billion globally

* Says Bausch + Lomb expects to submit a new drug application to the FDA for approval of Vesneo in mid-2015 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below